Source comparison
BPC-157 vs Cerebrolysin vs Semax: Mechanism and Timeline Comparison
When comparing peptides for concussion recovery, the most critical distinction is the injury phase each compound targets. BPC-157 acts in the acute phase (0–72 hours post-injury) when blood-brain barrier disruption and microvascular damage are most severe. Cer
This comparison does not assign a generated winner or score.
- When comparing peptides for concussion recovery, the most critical distinction is the injury phase each compound targets. BPC-157 acts in the acute phase (0–72 hours post-injury) when blood-brain barrier disruption and microvascular damage are most severe. Cerebrolysin is effective in the subacute phase (3–14 days) when secondary neuronal death occurs due to excitotoxicity and inflammation. Semax operates in the recovery phase (14+ days) when cognitive deficits persist despite structural healing.
- BPC-157's mechanism centres on VEGF (vascular endothelial growth factor) upregulation and eNOS (endothelial nitric oxide synthase) activation. Both promote angiogenesis and endothelial repair. In a 2021 rat TBI model published in Molecular Neurobiology, BPC-157 administration within 30 minutes of injury reduced cortical lesion volume by 48% at seven days post-injury. The dosing used was 10 mcg/kg intraperitoneally. Higher than typical gastrointestinal repair doses because CNS penetration requires systemic circulation.
- Cerebrolysin's neurotrophic activity mimics BDNF binding to TrkB receptors, triggering downstream PI3K/Akt survival pathways that prevent caspase-3-mediated apoptosis. A 2018 meta-analysis in CNS Drugs reviewed 13 TBI trials and found Cerebrolysin reduced mortality by 23% in moderate-to-severe cases when administered within 24 hours and continued for 10–21 days. Dosing ranged from 30–50 mL/day intravenously. Significantly higher volumes than most research peptides require.
- Semax operates through a dual mechanism: BDNF upregulation (similar to Cerebrolysin but via different pathways) and inhibition of enkephalin degradation, which modulates dopamine and serotonin signalling. The cognitive benefit is measurable 7–14 days after starting treatment. A 2020 study in Peptides found Semax restored Morris water maze performance in TBI rats to 85% of pre-injury baseline by day 21, compared to 62% in untreated controls. Standard research dosing is 300–600 mcg/kg via subcutaneous injection.